Gsa Capital Partners LLP Humanigen, Inc Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.15 - $3.02 $118,982 - $2.4 Million
793,218 Added 339.82%
1,026,643 $185,000
Q2 2022

Aug 09, 2022
BUY
$1.76 - $3.33 $185,570 - $351,108
105,438 Added 82.38%
233,425 $413,000
Q1 2022

May 11, 2022
BUY
$1.81 - $3.97 $5,080 - $11,143
2,807 Added 2.24%
127,987 $385,000
Q4 2021

Feb 14, 2022
BUY
$3.66 - $8.22 $458,158 - $1.03 Million
125,180 New
125,180 $466,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email